Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Patel

Showing results (141-150 of 152) with videos related to

Pageof 16
Sort By:
ACS Medicinal Chemistry Letters|February 21, 2015
An Orally Available BACE1 Inhibitor That Affords Robust CNS Aβ Reduction without Cardiovascular LiabilitiesYuan Cheng, James Brown, Ted C Judd, et al.
Bioorganic & Medicinal Chemistry Letters|May 25, 2005
Novel ketal ligands for the glucocorticoid receptor: in vitro and in vivo activityCameron J Smith, Amjad Ali, James M Balkovec, et al.
Journal of Medicinal Chemistry|February 19, 2008
Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activityMatthew W Martin, John Newcomb, Joseph J Nunes, et al.
Journal of Medicinal Chemistry|March 8, 2008
Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitorsMatthew M Weiss, Jean-Christophe Harmange, Anthony J Polverino, et al.
Journal of Medicinal Chemistry|March 8, 2008
Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluationJean-Christophe Harmange, Matthew M Weiss, Julie Germain, et al.
Journal of Medicinal Chemistry|August 6, 2010
Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitorVictor J Cee, Laurie B Schenkel, Brian L Hodous, et al.
Bioorganic & Medicinal Chemistry Letters|January 24, 2015
Development of 2-aminooxazoline 3-azaxanthenes as orally efficacious β-secretase inhibitors for the potential treatment of Alzheimer's diseaseJian Jeffrey Chen, Qingyian Liu, Chester Yuan, et al.
Journal of Medicinal Chemistry|March 7, 2008
Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activationErin F DiMauro, John Newcomb, Joseph J Nunes, et al.
Journal of Medicinal Chemistry|April 4, 2012
Design and preparation of a potent series of hydroxyethylamine containing β-secretase inhibitors that demonstrate robust reduction of central β-amyloidMatthew M Weiss, Toni Williamson, Safura Babu-Khan, et al.
Journal of Medicinal Chemistry|September 15, 2006
Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activityErin F DiMauro, John Newcomb, Joseph J Nunes, et al.
Pageof 16

Showing results (141-150 of 152) with videos related to

Sort By:
Pageof 16
ACS Medicinal Chemistry Letters|February 21, 2015
An Orally Available BACE1 Inhibitor That Affords Robust CNS Aβ Reduction without Cardiovascular LiabilitiesYuan Cheng, James Brown, Ted C Judd, et al.
Bioorganic & Medicinal Chemistry Letters|May 25, 2005
Novel ketal ligands for the glucocorticoid receptor: in vitro and in vivo activityCameron J Smith, Amjad Ali, James M Balkovec, et al.
Journal of Medicinal Chemistry|February 19, 2008
Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activityMatthew W Martin, John Newcomb, Joseph J Nunes, et al.
Journal of Medicinal Chemistry|March 8, 2008
Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitorsMatthew M Weiss, Jean-Christophe Harmange, Anthony J Polverino, et al.
Journal of Medicinal Chemistry|March 8, 2008
Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluationJean-Christophe Harmange, Matthew M Weiss, Julie Germain, et al.
Journal of Medicinal Chemistry|August 6, 2010
Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitorVictor J Cee, Laurie B Schenkel, Brian L Hodous, et al.
Bioorganic & Medicinal Chemistry Letters|January 24, 2015
Development of 2-aminooxazoline 3-azaxanthenes as orally efficacious β-secretase inhibitors for the potential treatment of Alzheimer's diseaseJian Jeffrey Chen, Qingyian Liu, Chester Yuan, et al.
Journal of Medicinal Chemistry|March 7, 2008
Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activationErin F DiMauro, John Newcomb, Joseph J Nunes, et al.
Journal of Medicinal Chemistry|April 4, 2012
Design and preparation of a potent series of hydroxyethylamine containing β-secretase inhibitors that demonstrate robust reduction of central β-amyloidMatthew M Weiss, Toni Williamson, Safura Babu-Khan, et al.
Journal of Medicinal Chemistry|September 15, 2006
Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activityErin F DiMauro, John Newcomb, Joseph J Nunes, et al.
Pageof 16